Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It never ceases to amaze me how some investors believe that a penny stock trading on the pink sheets should/would behave as though they were a Pfizer trading on one of the big boards.
Investors here are investing in a start-up company. Expectations should be tempered, and moderated. Success will not come overnight, and rewards will only come to those who have patience and nerves of steel. This venture is not for small children. There will be challenges and speed bumps. That's power for the course. This investment is speculation. As they say...."If one can't stand the heat, then get out of the kitchen".
This CEO would NOT conduct a SH conference call (and record it for the SEC to see and hear), if they were a scam! So the idea that they are a scam is nonsense. They are trying to build a business, and yes.... the insiders are not business majors from Harvard Business School. It's a start up company run by ambitious, eccentric entrepreneurs.
In addition, if the CEO is a scam, why would he POST the CC call recording for the world (and the SEC) to see his personal calendar?? Ask yourself that! He clearly is not hiding anything, else he would have never provided that recording to the open public exposing his personal calendar. This is "Common Sense".
As I've stated before, my biggest concern/worry, is they will not secure adequate funding to run business operations. Without that we run the risk of a R/S and repeat and rinse. Securing a viable business partner to fund operations is the Critical Success Factor with QNTA for the common SH. Or, if QNTA could secure a profitable deal (ex: Mexico) to elevate and sustain the PPS, then fund raising via moderate dilution would be feasible.
JMHO.... do your own DD.
Why do you believe that?
What I mean by broken is he often does not include both a subject and a predicate (ex: verb) in his sentences. When you compound that with a heavy accent, he will lose a chunk of his audiences. If the new co-CEO speaks proper English (regardless of the accent), that puts him light years ahead during a negotiations meeting. JMHO
Jedi..that is an EXCELLENT point you make regarding the new co-CEO !! The intent all along may have been to fill this gap/void.
It's not just the heavy accent. That's ON ME for having trouble with that. I need to work on that. It's his English sentences that are broken (not grammatically correct). His broken English IMO will hurt him in negotiations. Negotiating deals is just as much an art as it is a discipline. Good English and a command of the English vocabulary gives the negotiator a clear and major edge. I'm afraid that this CEO almost needs a translator in tough situations like that. Stakeholders need some form of deal NOW. Maybe he'll strike a deal with Mexico soon!
That won't help though if the person speaking has broken English. Also, English is the international language, so everyone should fine tune those skills. Yes, it does help to know other languages, however English is still the Top Gun in the business communities around the world. If you don't know English, the odds are you will be left behind. All of the excuses in the world won't stop that. The CEO is living and working in CA. His broken English will certainly hurt him in negotiating circles.
------------
Why English language is international language?
This is because English is the world's lingua franca or common second language, as this table shows. English is the international language of business, commerce, science, medicine, and many other key areas. Even in diplomacy, where French once ruled supreme, English is now dominant in most regions of the world
My issue is that I'm not that great at navigating through deep accents and broken English. It would be great if they transcribed the CC in English! I missed a few of the points due to my inability to understand some of the words spoken.
Jedi... In my opinion, your assessment here is "On Target" !! GLTA
Jedi..it was great to see the CEO and his team still hard at work behind the scenes!! There is a ton of misinformation (and disinformation) being ranted about, and it was prudent of the CEO to address the wild, unfounded FUD. This investment will require investor patience since it is essentially a startup company seeking to establish a viable foundation. There will be challenges, and they will need to navigate around them. Let's hope that the CEO is correct in that the SEC investigation should be soon behind them.
Biotech investments take time to work out. They are NOT for flippers or get-rich-quick schemers. It also takes money, so it is key (for the SH) that QNTA have success in securing private investors to fund the work ahead of them. Otherwise they will have to resort to extensive dilution, which will damage SH equity. So, we need to closely watch their success in their 'funding' efforts.
You might wish to post your question on the RLFTF 'discord' site/board?
That's an interesting point!
What if that assessment is wrong?
VERU will meet with the FDA by EOM, and they are currently making arrangments to submit EUA. We'll see if the FDA gives them preferential treatment over aviptadil. IMO their trial size was about as underpowered as the Dr JJ trial.
My question is....how effective does the new drug from VERU compete with Aviptadil? They both seem to be to treat the more advanced Covid disease.
Great Video of Fauci talking about Aviptadil. Starts at mark 38:50
Pulled the video from another poster
Aviptadil... The Last Drug Standing !!
https://stocktwits.com/HOID/message/458758780
No, I suspect that eventually we'll be flirting with sub penny on this one. Dr JJ only has one pot cooking on the stove, and NIH results are 6-12 months away. I think an R/S may be in the cards now, if the SEC permits that. I'm not sure if the ongoing litigation could be tying his hands on things. He really bungled this one! I wonder if he still posts that pic with him and his family/friends toasting wine on his yacht.
That down trend is not over!
I keep HGEN on my radar screen because I was long a few shares over a year ago. I got out before the R/S though. I haven't checked things for quite a while. Unfortunately it appears that the stock price hasn't held up well following that last R/S.
There won't be an R/S between now and June 5, 2022 PDUFA date.
Yes, there is much more inherent risk for those planning on holding this for years. However, there is much more reward potential for them if the cards fall right.
Different strokes for different folks.
Johnny.. However, that does not answer the question WHY? What does he have to gain by delaying the disclosure?
Any speculation as to why Tim won't disclose his source of FDA trial funding?
Profit Split between RLFTF and ACER on ACER-001 drug
Count Down till June 5, 2022 PDUFA date !!
RELIEF AND ACER THERAPEUTICS SIGN COLLABORATION AND LICENSE AGREEMENT FOR WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION OF ACER-001 FOR THE TREATMENT OF UREA CYCLE DISORDERS AND MAPLE SYRUP URINE DISEASE
22 March 2021
Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights
ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021
Geneva, Switzerland, and Newton, MA, USA, March 22, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, and Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the companies entered into a Collaboration and License Agreement (“CLA”) for worldwide development and commercialization of ACER-001. ACER-001 is a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be both taste-masked and immediate release.
Under the terms of the CLA, Acer will receive an approximately $10 million cash payment within 15 business days of CLA execution (originally $14 million, to be offset by repayment of the $4.0 million outstanding balance of the prior loan, plus interest, from Relief to Acer). Relief will also pay Acer up to $20 million in U.S. development and commercial launch costs for the UCDs and MSUD indications. Acer will retain development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan. The companies will split net profits from Acer’s territories 60%:40% in favor of Relief. In addition, Relief has licensed the rights for the rest of the world, where Acer will receive from Relief a 15% royalty on all revenues received in Relief’s territories. Acer may also receive a total of $6 million in development milestone payments following the first European (EU) marketing approvals for UCDs and MSUD.
gmoney..Among other things, everyone is waiting for .......
1) FDA PDUFA date of June 5, 2022
2) NIH Aviptadil trial results
I'm not 100% sure that the conversion only impacts the OTC. Regarding your question about purchasing new shares on the Swiss, you will have to ask someone who is more familiar with the Swiss exchange (I am not). Maybe another poster can respond to that.
The argument 'for the conversion' is that the price movements of the underlying shares on the Swiss will 'track with/to' the ADR shares (and vise versa). I personally do not buy into that notion.
Thanks Jed
Quote:
It's THE FLU and a variant of the common cold - and nothing more !!
My next door neighbor is a seasoned RN nurse, and he has been taking care of dying COVID patients for over 15 months in a local hospital. I can assure you ---. COVID is not just a variant of the common cold. The delta variant conducted mass murder on a global scale. The omicron variant is less dangerous, however it is still killing people who have immune systems that are compromised in any way. More variants will come. There is no assurance that the next variant won't be as deadly as delta. More and more evidence leads to the conclusion that this virus started in a lab, and hence it will be much tougher to stamp out. Another neighbor of mine refused to get the vaccine and died from blood clots stemming from COVID sickness.
In addition, Jadi has many, many more medical uses than just treating COVID. But everyone already knows that.
If I had a concern, it would be that the study may be considered (by the FDA) as underpowered (too small). I've seen this happen before. The FDA approves a study and then upon EUA evaluation they demand 'more data'. On the other hand, if Jadi's efficacy is stellar and knocks the primary endpoint out of the ballpark, they could stop the study early and go for early approval. Lot's of IFs.
Also, I sure hope that Tim secured a competent outfit to conduct the study. I've seen things go sideways or south before when the study was mishandled. Just go look at what happened to RLFTF. The CEO bungled the study and they got two EUA applications rejected, and now they are waiting for approval after a 3rd submittal. Big mess! Their study size was small too, just like the TSOI study.
I agree!!! COVID is not over by a long shot! No way!. That's wishful thinking by some. We have new variants on the loose and spreading. We'll have more variants going into this winter and into 2023. Former CDC Director Robert Redfield believes that we still have some very tough times ahead of us with COVID variants. In addition, the QNTA med has more applications than just COVID. One has to take the longer term view with this.
I'm sure that the QNTA attorney has told them that the prudent thing is to NOT discuss anything related to the SEC investigation. That's SOP.
Jed... you should add to the front of the list the open issue regarding WHAT did QNTA sell to US Farmatsevtik? Did they sell product, or part/all of the company? Dragon keeps putting forth the speculation that the COMPANY was sold to Farmatsevtik. Someone should record the call, unless that breaks any laws.
The high O/S is working against this penny stock, therefore clear 'progress' will need to be demonstrated to move the needle.
If the CEO is true to his word that an R/S will never occur 'on his watch', then one just needs to have a lot of patience to wait for 'progress' to be demonstrated. The PPS will then take care of itself.
Jedi...QNTA IR sent me an email a few months ago that a group of investors wishes to set up a special adhoc CC that they will work with a SH who wants to take a lead on that. If you want, and will fish out the email and forward it to you.
It's my understanding that 'forced' conversion of 150:1 will not occur until Level 3 is reached. And the conversion will only impact OTC shareholders (not holders who purchased shares directly off of the Swiss). The recent announcement was related to Level 2 only. So my guess is it may be middle or late summer before Level 3 is reached. Just a guess (I hope). It's also my understanding that RAM cannot dilute by dumping ADRs to raise $$ until after level 3 is reached.
I would much, much prefer if major progress was made on some of the key fronts (EUA, ACER-001, mediation, NIH, etc) BEFORE the forced 150:1 forced ADR Conversion takes place. We need a major PPS LIFT before that conversion IMO. Otherwise we are at risk of the PPS drifting south from $7.50 as the uncertainties linger on, which could devastate the SH (including GEM). RAM must know this! I've always wondered if GEM negotiated some sort of deal with RAM to protect GEM from that risk.
Great point Jedi!
Interesting!! I also found at least 2 phone numbers to dial to order product. So the argument that QNTA does not take phone calls to buy their products is false information. The first phone number appears to be a better phone number to inquire about placing an order.
Here is the 'product' POC on the 'contact us' link on the //aeliastore.com site.
(818) 940-1617
632 S Glenwood Place,
Burbank, CA, 91506
Here is the 'product' POC on 'contact us' link on the //medoliferx.com/shop site
Medolife Rx Headquarters
747-283-1818
632 S Glenwood Place,
Burbank, CA, 91506
Do you have their current web site address? The site posted on yahoo finance (https://www.BuyQuanta.com) no longer works.
What phone number have people been using to try and 'call' QNTA?
During the next CC someone should ask them that question. Why don't they take customer orders over the phone. Or at least pick up the phone and direct customers to their web site to place an order. Customers deserve an answer to that question.
Senator Ron Johnson rips the media over COVID. He mentioned "aviptadil".
He promoted drugs such as aviptadil, ivermectin and hydroxychloroquine.
The company that produces aviptadil has submitted a “breakthrough therapy designation” request to the U.S. Food and Drug Administration (FDA) this month in response to positive patient outcomes using the drug, according to a press release by the company last week. The FDA did not grant the designation in 2021 and requested more safety data, the company said.
https://www.riponpress.com/news/wisconsin-sen-ron-johnson-rails-against-the-media-public-health-agencies-at-green-lake-event/article_a2921f7a-c636-11ec-bd5b-7b4e36d7a6de.html